Carisma Therapeutics Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Carisma Therapeutics Inc 's ROA in the third quarter of 2025?
Carisma Therapeutics Inc achieved a return on average assets (ROA) of 528.22 % in its third quarter of 2025 a new company high.

ROA has improved compared to -163.79% in the second quarter of 2025, due to net income growth.

However, within the Healthcare sector Carisma Therapeutics Inc achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 14, from total ROA ranking in the second quarter of 2025 at 4617.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-84.42 %	-91.55 %	-78.38 %	-66.62 %	-60.61 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	77	-38	-41	-60	-105
Return On Assets (TTM)	528.22 %	-163.79 %	-111.1 %	-117.63 %	-157.67 %
CARM's Total Ranking	# 14	# 4617	# 4569	# 5298	# 4790
Total Assets (TTM) in million	7	5	16	30	42
Seq. Total Assets Change	30.77 %	-68.58 %	-47.62 %	-27.58 %	-29.12 %
Seq. Net Income Change	-	-	-	-	-

CARM's 5 Years Annual ROA >> Back to CARM Management Effectiveness >> Compare CARM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 0
Sector	# 0
Overall	# 12

Return On Assets Statistics
High	Average	Low
528.22 %	-36.02 %	-163.79 %
(Sep 30 2025)		(Jun 30 2025)

Financial Statements
Carisma Therapeutics Inc 's Assets	$ 7 million	CARM's Balance sheet
Carisma Therapeutics Inc 's Income	$ 89 million	Quarterly CARM's Income Statement
CARM's Income by Division		See CARM's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-65.99 %	-52.67 %	-21.41 %	96.01 %	7.4 %
Total Assets in million	30	90	189	241	123
Y / Y Net Income Change	-	-	-53.16 %	-	-
Net Income in million	-60	-87	4	8	-2
Annual Return On Assets	-198.56 %	-97.01 %	2.05 %	3.44 %	-1.3 %

CARM's 5 Years Annual ROA >> Back to CARM Management Effectiveness >> Compare CARM ROA to its Competitors

More Return On Assets Ratios
CARM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CARM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CARM's Competitors
Subscribers only: Roa for Carisma Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CARM's Customers

You may also want to know
CARM's Roi	CARM's Inventory Turnover Ratio	CARM's Growth Rates	CARM's Dividend Comparisons
	CARM's Profitability Ratios	CARM's Asset Turnover Ratio	CARM's Dividend Growth
CARM's Roe	CARM's Valuation Ratios	CARM's Financial Strength Ratios	CARM's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector	ROA
Carisma Therapeutics Inc	528.22 %
Vystar Corporation	437.97 %
Glucotrack Inc	303.77 %
One World Products Inc	233.44 %
Kyntra Bio Inc	124.15 %

Date modified: 2026-09-26T06:59:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.